Phathom Pharmaceuticals Inc
NASDAQ:PHAT

Watchlist Manager
Phathom Pharmaceuticals Inc Logo
Phathom Pharmaceuticals Inc
NASDAQ:PHAT
Watchlist
Price: 9.42 USD -7.56% Market Closed
Updated: Jun 2, 2024

Phathom Pharmaceuticals Inc
Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Phathom Pharmaceuticals Inc
Cash Equivalents Peer Comparison

Comparables:
JNJ
BMY
PFE
MRK
LLY

Competitive Cash Equivalents Analysis
Latest Figures & CAGR of Competitors

Company Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Phathom Pharmaceuticals Inc
NASDAQ:PHAT
Cash Equivalents
$381.4m
CAGR 3-Years
10%
CAGR 5-Years
235%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Cash Equivalents
$3.8B
CAGR 3-Years
22%
CAGR 5-Years
-2%
CAGR 10-Years
-15%
Bristol-Myers Squibb Co
NYSE:BMY
Cash Equivalents
$9.3B
CAGR 3-Years
-5%
CAGR 5-Years
5%
CAGR 10-Years
6%
Pfizer Inc
NYSE:PFE
Cash Equivalents
$719m
CAGR 3-Years
-26%
CAGR 5-Years
-18%
CAGR 10-Years
-13%
Merck & Co Inc
NYSE:MRK
Cash Equivalents
$5.6B
CAGR 3-Years
-7%
CAGR 5-Years
-7%
CAGR 10-Years
-10%
Eli Lilly and Co
NYSE:LLY
Cash Equivalents
$2.5B
CAGR 3-Years
-6%
CAGR 5-Years
4%
CAGR 10-Years
-4%

See Also

What is Phathom Pharmaceuticals Inc's Cash Equivalents?
Cash Equivalents
381.4m USD

Based on the financial report for Dec 31, 2023, Phathom Pharmaceuticals Inc's Cash Equivalents amounts to 381.4m USD.

What is Phathom Pharmaceuticals Inc's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
235%

Over the last year, the Cash Equivalents growth was 145%. The average annual Cash Equivalents growth rates for Phathom Pharmaceuticals Inc have been 10% over the past three years , 235% over the past five years .